Influence of MRP4 levels on clinical outcomes in biliary tract cancer.

• DOI: 10.1200/jco.2025.43.4_suppl.624
• Publication Date: 2025-01-27T14:34:47Z
• Authors: Gerardo F. Arroyo; Ana Sahores; Ana Carolina Ituarte; Cristina Inklemona; Sandra Rojo; Ruben Dario Kowal...; Carlos Davio; Maria May
• Keywords: Biliary Tract Cancer

624 Background: Biliary tract cancer (BTC) are rare tumors with a poor prognosis.Multidrug resistance protein 4 (MRP4) is transmembrane efflux transporter that influences on cellular growth and differentiation. Recent studies have linked high MRP4 levels to increased aggressiveness in pancreatic other tumor types. This study aimed evaluate the role of BTC its association clinical outcomes real-world cohort from endemic areas Argentina. Methods: We conducted retrospective analysis expression paraffin-embedded tissue samples 78 patients BTC. Immunohistochemistry staining was performed, scored based intensity percentage positive cells. A score exceeding 100 classified as levels. Statistical analyses included Chi-square, Kaplan-Meier survival curves, log-rank tests, significance set p <0.05 (two-tailed). Results: High were observed 46 out (59%). Patients gallbladder (n=64) elevated had significantly poorer overall (OS) compared those low (median 11.3 14.5 months, low, =0.038). In broader evaluable for (n=73; 64 gallbladder, 7 cholangiocarcinoma, 1 ampulla Vater, biliary undefined) non-significant shorter OS 12.4 13.5 =0.17). Poorly differentiated more likely express ( =0.06). found 59% localized stages (0-II) 57% advanced (III, IV relapsed). Conclusions: common BTC, particularly cancer, could be marker prognosis. appear poorly tumors, similar both, early stages, suggesting involvement progression. Further prospective needed confirm biomarker. If driver gene, targeting inhibitors represent promising therapeutic strategy these challenging tumors.